Comparing GnRH Agonists and Antagonists for Endometriosis Pain

In "Comparing GnRH Agonists and Antagonists for Endometriosis Pain," Dr. Davitt explains the mechanistic split between two major drug classes used to manage endometriosis pain.

Dr. Davitt walks through how GnRH agonists and antagonists differ mechanistically at the GnRH receptor. Agonists initially activate the receptor before ultimately preventing future activation through continued binding, producing an initial flare in hormone secretion followed by suppression. Antagonists, by contrast, directly block the receptor from the start of therapy, shutting down hormone output without that initial flare. Despite this mechanistic difference, both classes produce similar downstream effects on pain relief. Dr. Davitt notes there is some evidence of disease regression as well: early studies using repeat laparoscopy visualized changes in lesions, and newer data has shown decreases in endometrioma size with GnRH agonist therapy specifically. Across the available studies, the main outcomes consistently point to decreased menstrual and intermenstrual pain, with some antagonists also demonstrating a specific reduction in dyspareunia. The discussion then turns to how he counsels patients about the hypoestrogenic side effects both drug classes share. Dr. Davitt divides these into two groups. The first affects quality of life day to day, including hot flushes, night sweats, trouble sleeping, and mood changes, all of which appear with both agonists and antagonists and warrant a detailed conversation about what to expect. The second group is medically significant for long-term health but often isn't something the patient personally feels, namely bone mineral density loss. He stresses that this loss needs active screening and management, especially with longer courses of treatment, precisely because patients won't notice it the way they notice hot flushes or sleep disruption. Framing side effects this way, Dr. Davitt says, helps patients understand which symptoms to expect immediately and which require ongoing monitoring even when they feel fine day to day.

The next episode in this series, "Choosing Between Newer GnRH Antagonist Therapies for Endometriosis," features Dr. Davitt comparing two newer therapies patients ask about by name.